Medpace Holdings, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report. Medpace is a global clinical research organization providing Phase I–IV development services to pharmaceutical, biotechnology, and medical-device companies.
Financial results and liquidity
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $925.9 million | $861.0 million | +7.5% |
| Operating income | $167.0 million | $127.3 million | +31.3% |
| Operating margin | 18.0% | 14.8% | +3.2 percentage points |
| Net income | $145.4 million | $100.4 million | +44.7% |
| Diluted EPS | $3.84 | $2.67 | +43.8% |
| Operating cash flow | $258.7 million | $201.9 million | +$56.8 million |
| Cash and cash equivalents at year-end | $277.8 million | $131.9 million | +$145.8 million |
- Net margin was approximately 15.7%, compared with 11.7% in 2019. Lower SG&A and amortization, improved operating income, and a lower effective tax rate contributed to earnings growth. The effective tax rate declined to 13.7% from 19.5%, principally due to share-based compensation tax benefits and other tax benefits.
- Total direct costs increased 5.2% to $647.2 million, below revenue growth; SG&A declined 3.2% to $92.2 million, largely reflecting lower travel costs during COVID-19. Revenue includes $292.8 million of reimbursed out-of-pocket costs, which are presented gross.
- Net cash used in investing activities was $31.2 million, mainly capital expenditures. Operating cash flow less property and equipment expenditures was approximately $227.3 million, versus $184.0 million in 2019.
- No borrowings were outstanding under the unsecured $50 million credit facility at year-end; $49.8 million was available, with $0.2 million of letters of credit outstanding. The facility was due to expire March 31, 2021. The company reported no long-term debt and compliance with financial covenants.
- Operating lease liabilities totaled $131.0 million. Contractual operating lease payments were $196.5 million, including $22.4 million due within one year.
Business trends and changes from 2019
- Net new business awards rose to $1.175 billion from $1.094 billion. Backlog increased 20.1% to $1.542 billion at year-end, including an estimated $785–$805 million expected to convert to revenue in 2021. Management cautions that backlog is not a reliable predictor: contracts are generally terminable, and timing, scope changes, and cancellations affect conversion.
- Oncology revenue increased to $297.7 million from $256.8 million; antiviral and anti-infective revenue increased to $103.3 million from $86.4 million. Metabolic and CNS revenue declined year over year.
- Small and mid-sized biopharmaceutical clients generated approximately 75% and 15% of 2020 revenue, respectively. No individual customer represented 10% or more of revenue.
- Medpace repurchased 1.18 million shares for $98.3 million during 2020, including $47.4 million in the fourth quarter. It ended the year with $102.6 million of remaining authorization. The company has not paid dividends and reports no current plans to do so.
Outlook, risks, and unusual items
- COVID-19 materially disrupted 2020 operations: reduced trial starts, slower awards and patient recruitment, travel restrictions, and site disruption affected service delivery. Labs remained operational with safety modifications; virtual monitoring was among the mitigation measures. Medpace reduced staff in certain geographies and said the pandemic could continue to materially affect results; its future financial impact could not be reasonably estimated.
- The filing provides no specific revenue or earnings guidance. Management expected liquidity to be sufficient for the next 12 months and longer term, based on cash, operating cash flows, and available borrowing capacity.
- Key business risks include customer cancellations or inability to fund trials, backlog conversion uncertainty, fixed-fee contract cost overruns or delayed change-order approvals, recruitment and enrollment challenges, competition and pricing pressure, and dependence on qualified staff and third-party providers.
- Additional risks include clinical-trial quality and patient-safety liability, regulatory and privacy compliance, cybersecurity and system availability, foreign-exchange exposure, and the effects of international operations. A 10% exchange-rate movement was estimated to change 2020 pretax income by about $8.8 million in either direction.
- Revenue recognition depends on estimates of costs to complete clinical research contracts; the auditor identified this as a critical audit matter. Actual cost estimates and scope changes may cause cumulative revenue adjustments.
- CEO and founder August J. Troendle controlled approximately 20.2% of outstanding shares. The company also disclosed related-party leases involving entities owned by the CEO and other related-party business dealings. These warrant review for governance, terms, and potential conflicts.
- Management and the auditor concluded internal control over financial reporting was effective; the auditor issued unqualified opinions on the financial statements and controls. Management said pending legal matters were not expected to have a material adverse effect.
Important facts for investors to verify
- Whether the $785–$805 million of backlog expected to convert in 2021 converted on schedule, and how cancellations or scope changes affected the remainder.
- Whether COVID-related site disruption, trial starts, recruitment, and client funding recovered or continued to pressure revenue and staffing.
- Whether the $50 million credit facility was extended or replaced before its March 31, 2021 expiration.
- How contract cost-to-complete estimates, fixed-fee economics, and approved change orders affected margins and revenue recognition.
- The terms and oversight of CEO-related leases and other related-party transactions, alongside the CEO’s substantial voting influence.